

Net Results Plus Update October 1 , 2022 Formulary Changes

The information below is effective as of October 1, 2022 and applies to all commercial employer groups that are assigned to the Net Results Plus formulary. All changes to this list are the result of a comprehensive review of relevant clinical information by the Prime Therapeutics National Pharmacy and Therapeutics Committee.

Brand Name Drugs available with generic equivalents (Excluded from coverage)

For application across all commercial formularies the following Brand-name drugs are now **available with generic equivalents**, as a result the Brand name will be **excluded** from coverage effective October 1, 2022. The generic equivalent will continue to be covered.

ACZONE GEL	FERRIPROX TAB	STALEVO 50
BIDIL TAB	K-PHOS TAB	VIMPAT TAB
COMBIGAN OPTH SOL	SAMSCA TAB 15MG	ZIPSOR CAP
ESBRIET TAB		

Brand Name and generic Drugs with available alternatives (Excluded from coverage)

The following generic and Brand-name drugs with preferred alternatives will be **excluded** from coverage effective October 1, 2022, Request for coverage will require documented medical necessity.

APO-VARENICLINE	VYVANSE CAP	UKONIQ TAB 200MG
	VYVANSE CHW 10MG	

Tier changes

The following products have been moved to a **higher** co-pay tier effective October 1, 2022.

Tier 1 to Tier 3

DEXAMETHASON TAB 0.5MG	MOXIFLOXACIN SOL	TRIHEXYPHENIDIL SOL
DEXAMETHASON TAB 0.75MG	QUINIDINE SULF TAB	VANAZOLE GEL
MORPHINE SUL CAP ER	SULFADIAZINE TAB	ZOLPIDEM TAR SUBLINGUAL
MORPHINE SUL SOL	TRAMADOL HCL TAB ER	